https://su056inhibitor.com/nlr....p3-inflammasome-acco
Intriguingly, the JAK/STAT pathway is central to both the inflammatory and immune methods and it is a pathway already focused by other RA treatments. We suggest that the DMARD activity of MTX is going to be mostly mediated by its inhibition of JAK/STAT pathway signalling while several of its side effects are most likely associated with the folate path. This insight into the mechanism-of-action of MTX starts the alternative for repurposing
Like
Comment
Share
